Synthesis and biological evaluation of C-2 halogenated analogs of salvinorin A.
Salvinorin A (1), the main active ingredient of Salvia divinorum, is a potent and selective κ opioid receptor (KOPR) agonist. Based on the SAR, its C-2 position is one of the key binding sites and has very little space tolerance (3-4 carbons atoms) and limited to only lipophilic groups. In our attempt to prepare PET brain imaging agent for mapping KOPR, a series of C-2 halogenated analogs have been synthesized and screened for binding affinity at κ (KOPR), μ (MOPR), and δ (DOPR). These C-2 halogenated analogs with sequential changes of atomic radius and electron density serve as excellent molecular probes for further investigating the binding pocket at C-2, particularly on the effects of α verses β configuration at C-2 position. The results of KOPR binding and functional studies reveal β isomer in general binds better than α isomer with the exception of iodinated analogs and none of the C-2 halogenated analogs shows any improvement of KOPR binding affinity. Interestingly, functional assay has characterized that 6b is a partial agonist with E(max) of 46% of the kappa receptor full agonist U50,488H at 250 nM (K(i)). We have also observed that the affinity to the kappa receptor increases with atomic radius (I>Br>Cl>F) which is in good agreement with halogen bonding interactions reported in the literature.
Lee
David Y W
DY
Bio-Organic and Natural Products Laboratory, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA. DLee@mclean.harvard.edu
Yang
Lu
L
Xu
Wei
W
Deng
Gang
G
Guo
Lin
L
Liu-Chen
Lee-Yuan
LY
D045785:Diterpenes, Clerodane / Q000138:chemical synthesis* / Q000737:chemistry; D054879:Halogenation; D007536:Isomerism; D007700:Kinetics; D049268:Positron-Emission Tomography; D011485:Protein Binding; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000378:metabolism; D027544:Salvia / Q000737:chemistry; D013329:Structure-Activity Relationship
D045785:Diterpenes, Clerodane; D017473:Receptors, Opioid, kappa; C090499:salvinorin A
Bioorg Med Chem Lett. 2005 Aug 15;15(16):3744-7
15993589
Org Lett. 2002 Feb 21;4(4):553-5
11843589
Chem Rev. 2008 May;108(5):1732-43
18476672
J Ethnopharmacol. 1994 Jun;43(1):53-6
7526076
Org Lett. 2005 Jul 7;7(14):3017-20
15987194
Tetrahedron Lett. 2008 Feb 4;49(6):937-940
19197341
J Pharmacol Exp Ther. 2008 Mar;324(3):1073-83
18089845
J Med Chem. 2008 Apr 24;51(8):2421-31
18380425
Bioorg Med Chem Lett. 2006 Sep 1;16(17):4679-85
16777411
Trends Pharmacol Sci. 2003 Mar;24(3):107-9
12628350
Bioorg Med Chem. 2009 Feb 1;17(3):1370-80
19147366
Bioorg Med Chem. 2008 Feb 1;16(3):1279-86
17981041
J Med Chem. 2009 May 14;52(9):2854-62
19358610
J Pharmacol Exp Ther. 2009 Feb;328(2):588-97
19001155
J Med Chem. 2005 Jan 27;48(2):345-8
15658846
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11934-9
12192085
Drug Alcohol Depend. 2006 Nov 8;85(2):157-62
16720081